The World Health Organization’s CBD pre-review report

It’s no surprise that people prefer natural alternatives to alleviate pain, inflammation, and mental imbalances. And it’s no secret that CBD is at the top of the natural remedies for any physical or mental condition. CBD has many potential therapeutic benefits. While the FDA doesn’t regulate CBD, the World Health Organization has published a CBD pre-review report. They address some of the most common concerns about cannabidiol such as potential side effects, tolerance, and abuse, medical uses, etc. Let’s take a closer look at what the World Health Organization CBD pre-review report says.

CBD: A Summary

CBD or Cannabidiol is one of the more than 100 cannabinoids present in hemp. It is found to be non-psychoactive and attaches to the receptors in the Endocannabinoid System to bring about the potential benefits it offers. And it is legal in all 50 states under the 2018 Farm Bill.

CBD side effects

According to the World Health Organization (WHO) CBD pre-review report, cannabidiol is well tolerated by animals and human beings and does not cause adverse reactions. Many controlled studies and clinical trials have shown that even with a high dosage, CBD seems to have a good safety profile.

CBD dependence potential

Even though CBD is extracted from Hemp, it has no potential to create dependence. Unlike THC, CBD is well tolerated by humans and does not present any signs of physical dependence effects.

A study published in 2019 took a look at that. Based on the results, CBD was found to not get the participants addicted. It can actually help as part of addiction treatment. This gives a strong basis for the safety of CBD. Although it’s not the final evidence, it provides further proof about this chemical’s potential safety and efficacy.

What does the WHO say about CBD?

At this time, the FDA is still not regulating CBD. In fact, they are discouraging people from using CBD. This report signifies that aside from Epidiolex, they are not considering CBD as part of therapeutics due to a lack of clinical trials. But since Epidiolex has passed clinical trials as a treatment to reduce seizures for epileptic patients, seems very clear that CBD does have therapeutic properties and it can help many people improve their lifestyle.

The CDC agreed that CBD will not cause the ‘high’ effect, but still warn the public of its potential dangers mainly due to the lack of regulation on the market and not really knowing what certain brands put in their ingredient list.

The World Health Organization CBD pre-review report concludes that “CBD exhibits no effects indicative of any abuse or dependence”. The report added that “CBD is generally well tolerated with a good safety profile. Reported adverse effects may be as a result of drug-drug interactions between CBD and patients’ existing medications.” and “To date, there is no evidence of recreational use of CBD or any public health-related problems associated with the use of pure CBD.”


Yes, government agencies that are responsible for our health are advising people against CBD because of a lack of research. But the scientific community is also pleading with the government and other financial sources to back them up in pushing the CBD research forward.

Anecdotal evidence of CBD’s potential benefits is hard to disregard. But researching about its safety profile is important as well. Initial studies concluded that CBD is well tolerated by humans and a further proof will be provided the more we study CBD. 

    Your Cart
    Your cart is emptyReturn to Shop